Clinical Trial Update: Ph 2 Open Label Study of GC4419 to Reduce SOM Associated With Chemoradiotherapy for Head and Neck Cancer [Phase 2]

View source ↗

Summary

Phase 2 open-label study evaluating GC4419 to reduce severity of oral mucositis associated with chemoradiotherapy in head and neck cancer; study completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Head and Neck Cancer
• Oral Mucositis

Drugs mentioned

• GC4419

Snippet

Sponsor: Galera Therapeutics, Inc. | Conditions: Head and Neck Cancer, Oral Mucositis | Phase 2 | Status: COMPLETED | Results posted: 2022-08-16